Skip to Content

Erleada (apalutamide) Disease Interactions

There are 5 disease interactions with Erleada (apalutamide):

Moderate

Apalutamide (applies to Erleada) CV events

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Ischemic Heart Disease, Diabetes Mellitus, Hypertension, Hyperlipidemia

Ischemic cardiovascular events, including events leading to death, occurred in patients receiving apalutamide. It is recommended to monitor for signs and symptoms of ischemic heart disease and to consider discontinuation of treatment for Grade 3 and 4 events. Care should be exercised when prescribing this agent in patients at risk of an ischemic cardiovascular event, such as in those patients with hypertension, diabetes, or dyslipidemia.

Moderate

Apalutamide (applies to Erleada) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

No clinically significant differences in the pharmacokinetics of apalutamide or its major metabolite were observed in patients with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment. The effect on patients with severe hepatic impairment (Child-Pugh C) on apalutamide pharmacokinetics is unknown. Close monitoring of liver function is recommended in these patients.

Moderate

Apalutamide (applies to Erleada) osteoporosis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Metabolic Bone Disorder, Metabolic Disorder - Congenital

Falls and fractures have occurred in patients receiving apalutamide. Care should be exercised when apalutamide is used in patients at risk for fractures or falls and in those patients with osteoporosis. It is recommended to evaluate patients for fracture and fall risk and to consider the use of bone-targeted agents as medically necessary.

Moderate

Apalutamide (applies to Erleada) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

No clinically significant differences in the pharmacokinetics of apalutamide or its major metabolite were observed in patients with mild to moderate renal impairment. The effect on patients with severe renal impairment or end-stage renal disease on apalutamide pharmacokinetics is unknown. Close monitoring of renal function is recommended in these patients.

Moderate

Apalutamide (applies to Erleada) seizure

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures

The use of apalutamide may cause seizures. It is recommended to discontinue this agent in patients who develop a seizure while on treatment. Care should be exercised when using apalutamide in patients at risk or with a history of seizure disorder.

Erleada (apalutamide) drug interactions

There are 544 drug interactions with Erleada (apalutamide)

Erleada (apalutamide) alcohol/food interactions

There are 2 alcohol/food interactions with Erleada (apalutamide)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.